MA27002A1 - Amides d'acide anthranilique, procede pour les preparer, leur utilisation comme antiarythmiques et preparations pharmaceutiques les contenant - Google Patents

Amides d'acide anthranilique, procede pour les preparer, leur utilisation comme antiarythmiques et preparations pharmaceutiques les contenant

Info

Publication number
MA27002A1
MA27002A1 MA27313A MA27313A MA27002A1 MA 27002 A1 MA27002 A1 MA 27002A1 MA 27313 A MA27313 A MA 27313A MA 27313 A MA27313 A MA 27313A MA 27002 A1 MA27002 A1 MA 27002A1
Authority
MA
Morocco
Prior art keywords
anthranilic acid
pharmaceutical preparations
preparations containing
antiarrhythmics
amides
Prior art date
Application number
MA27313A
Other languages
English (en)
Inventor
Joachim Brendel
Bernard Pirard
Stefan Peukert
Heinz-Werner Kleemann
Horst Hemmerle
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MA27002A1 publication Critical patent/MA27002A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Amides d'acide anthranilique, procédé pour les préparer, leur utilisation comme antiarythmiques et préparations pharmaceutiques les contenant L'invention concerne des amides d'acides anthraniliques, un procédé pour leur production, leur utilisation comme médicament, et des préparations pharmaceutiques contenant ces amides d'acide anthranilique. Les amides d'acide anthranilique consistent en composés de formule I oé R1 à R7 ont les significations citées dans les revendications, agissent sur le canal potassique Kv1.5 et inhibent un courant de potassium décrit comme étant un "ultra-rapidly activating delayed rectifier" dans l'oreillette cardiaque humaine. Les composés sont donc particulièrement appropriés comme nouvelles substances actives antiarythmiques, en particulier pour traiter et prévenir les arythmies auriculaires, par exemple la fibrillation auriculaire AF ou le battement auriculaire.
MA27313A 2001-04-28 2003-09-16 Amides d'acide anthranilique, procede pour les preparer, leur utilisation comme antiarythmiques et preparations pharmaceutiques les contenant MA27002A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10121003A DE10121003A1 (de) 2001-04-28 2001-04-28 Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
MA27002A1 true MA27002A1 (fr) 2004-12-20

Family

ID=7683152

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27313A MA27002A1 (fr) 2001-04-28 2003-09-16 Amides d'acide anthranilique, procede pour les preparer, leur utilisation comme antiarythmiques et preparations pharmaceutiques les contenant

Country Status (36)

Country Link
US (2) US7235690B2 (fr)
EP (1) EP1385820B1 (fr)
JP (1) JP4231295B2 (fr)
KR (1) KR100865250B1 (fr)
CN (1) CN100522937C (fr)
AR (1) AR033623A1 (fr)
AT (1) ATE528288T1 (fr)
AU (1) AU2002338494B2 (fr)
BG (1) BG108215A (fr)
BR (1) BR0209185A (fr)
CA (1) CA2445341C (fr)
CR (1) CR7099A (fr)
CZ (1) CZ20032921A3 (fr)
DE (1) DE10121003A1 (fr)
EC (1) ECSP034780A (fr)
EE (1) EE05267B1 (fr)
HK (1) HK1064663A1 (fr)
HR (1) HRP20030871A2 (fr)
HU (1) HUP0304043A3 (fr)
IL (2) IL158504A0 (fr)
MA (1) MA27002A1 (fr)
MX (1) MXPA03008419A (fr)
MY (1) MY143521A (fr)
NO (1) NO328872B1 (fr)
NZ (1) NZ529129A (fr)
OA (1) OA12598A (fr)
PE (1) PE20021088A1 (fr)
PL (1) PL363433A1 (fr)
RS (1) RS82003A (fr)
RU (1) RU2283833C2 (fr)
SK (1) SK13262003A3 (fr)
TN (1) TNSN03084A1 (fr)
TW (1) TWI259833B (fr)
UA (1) UA76986C2 (fr)
WO (1) WO2002088073A1 (fr)
ZA (1) ZA200306991B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
BR0309522A (pt) * 2002-04-26 2005-02-09 Ishihara Sangyo Kaisha Compostos piridina ou sais destes e herbicidas contendo os mesmos
DE10312073A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
US20040192738A1 (en) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
MXPA06001550A (es) 2003-08-08 2006-09-04 Johnson & Johnson Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de a colecistocinina 2.
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
CN101061116A (zh) * 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB2434794A (en) * 2006-02-03 2007-08-08 Prom Ltd Continuous process for forming anthranilic acid and treatment of waste water containing organic material
US7678818B2 (en) * 2006-02-07 2010-03-16 Hoffmann-La Roche Inc. Anthranilamide and 2-amino-heteroarene-carboxamide compounds
CN101636154B (zh) * 2006-04-27 2011-12-14 塞诺菲-安万特德国有限公司 Task-1和task-3离子通道抑制剂
MX2011000051A (es) * 2008-07-07 2011-07-28 Fasgen Inc Nuevos compuestos, composiciones farmaceuticas que contienen los mismos, metodos para usar los mismos, y metodos para preparar los mismos.
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
MX2013015058A (es) 2011-06-24 2014-01-20 Amgen Inc Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos.
CN103906733A (zh) 2011-06-24 2014-07-02 安姆根有限公司 Trpm8拮抗剂及其在治疗中的用途
NO3175985T3 (fr) 2011-07-01 2018-04-28
NZ627942A (en) 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
CN103130696B (zh) * 2013-03-21 2014-06-11 山东大学 邻氨基苯甲酰胺类化合物及其制备方法与应用
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
KR101893836B1 (ko) 2016-07-11 2018-08-31 김종해 식물성 대체 우유 제조 방법과 시스템
BR112021006225A2 (pt) 2018-10-02 2021-07-06 Syngenta Participations Ag compostos de benzeno- e azina-amida ativos em termos pesticidas
CN111285806B (zh) * 2018-12-06 2022-04-15 中国医学科学院药物研究所 吡唑类化合物及其制备方法、用途和药物组合物
UY38623A (es) 2019-03-29 2020-10-30 Syngenta Crop Protection Ag Compuestos de diazina-amida activos como pesticidas
WO2020201398A1 (fr) 2019-04-05 2020-10-08 Syngenta Crop Protection Ag Composés de diazine-amide à action pesticide
US20220169629A1 (en) 2019-04-11 2022-06-02 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
EP4017851A1 (fr) 2019-08-23 2022-06-29 Syngenta Crop Protection AG Composés de pyrazine-amide à action pesticide
CN114630825A (zh) 2019-11-01 2022-06-14 先正达农作物保护股份公司 杀有害生物活性的稠合二环杂芳香族化合物
WO2021151926A1 (fr) 2020-01-30 2021-08-05 Syngenta Crop Protection Ag Composés aminés hétéroaromatiques bicycliques condensés à action pesticide
CN115244036A (zh) 2020-02-27 2022-10-25 先正达农作物保护股份公司 杀有害生物活性的二嗪-双酰胺化合物
WO2022101265A1 (fr) 2020-11-13 2022-05-19 Syngenta Crop Protection Ag Composés hétéroaromatiques bicycliques fusionnés à action pesticide
WO2022258481A1 (fr) 2021-06-09 2022-12-15 Syngenta Crop Protection Ag Composés diazine-amides à action pesticide
AU2022299145A1 (en) 2021-06-24 2023-12-07 Syngenta Crop Protection Ag 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides
EP4377312A1 (fr) 2021-07-29 2024-06-05 Syngenta Crop Protection AG Composés hétéroaromatiques bicycliques fusionnés à action pesticide
WO2023072849A1 (fr) 2021-10-27 2023-05-04 Syngenta Crop Protection Ag Composés de pyridazinone à action pesticide
WO2023104714A1 (fr) 2021-12-10 2023-06-15 Syngenta Crop Protection Ag Composés de pyridazinone à action pesticide
WO2023247360A1 (fr) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Composés hétéroaromatiques bicycliques fusionnés à action pesticide
WO2024110554A1 (fr) 2022-11-23 2024-05-30 Syngenta Crop Protection Ag Dérivés de n-[(1-[2-[6-(pyridazin-3-yl]-1,2,4-triazol-3-yl]éthyl]-quinazolin-4-amine et de n-[1-[3-(6-(pyridazin-3-yl)pyrazin-2-yl]éthyl]-8-quinazolin-4-amine utilisés en tant que pesticides
WO2024133551A1 (fr) 2022-12-21 2024-06-27 Syngenta Crop Protection Ag Composés de pyridazine à activité pesticide

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3497529A (en) 1967-03-23 1970-02-24 Sandoz Ag Benzamides
PT77219B (fr) * 1982-08-24 1986-02-04 May & Baker Ltd Procede de preparation des derives de la benzamide
DE4035961A1 (de) 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2057324A1 (fr) 1990-12-18 1992-06-19 Lora Louise Fitch Agents hypoglycemiques de type benzamide et sulfonamide
DE4127404A1 (de) 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4236045A1 (de) 1992-04-03 1993-11-04 Teves Gmbh Alfred Hydraulisches umschaltventil fuer eine fahrzeugbremsanlage
NO922913L (no) 1992-07-22 1994-07-22 Iver Hansen Hurtigpiggede dekk
WO1994015913A1 (fr) 1992-12-30 1994-07-21 Smithkline Beecham Corporation Composes chimiques
JP2861743B2 (ja) * 1993-07-16 1999-02-24 住友電装株式会社 コネクタ端子のジョイント構造
HUT74450A (en) 1993-12-27 1996-12-30 Eisai Co Ltd Anthranilic acid derivative and pharmaceutical compns. contg. such compds.
US5436229A (en) 1994-03-04 1995-07-25 Eli Lilly And Company Bisulfite adducts of arginine aldehydes
US5447819A (en) 1994-05-27 1995-09-05 Eastman Kodak Company Photographic element containing high dye-yield couplers having improved reactivity
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5638980A (en) * 1995-09-29 1997-06-17 Parks; Joseph R. Fluid storage safety device
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
EP1026160A4 (fr) 1997-09-16 2003-01-22 Takeda Chemical Industries Ltd Composes azotes a cycles condenses, procede de preparation de ces composes et medicaments
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
CA2315070A1 (fr) 1997-12-17 1999-07-01 Schering Aktiengesellschaft Derives d'(ortho)-anthranilamide comme anticoagulants
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
EP1082315A1 (fr) 1998-06-05 2001-03-14 Icagen, Inc. Inhibiteurs des canaux de potassium
DE19837211A1 (de) 1998-08-17 2000-02-24 Basf Ag Verfahren zur Herstellung von Alkindiolen
AU754204B2 (en) 1998-09-01 2002-11-07 Bristol-Myers Squibb Company Potassium channel inhibitors and method
AU4431400A (en) 1999-05-12 2000-12-05 Japan As Represented By President Of National Cancer Center Anticancer agents containing ep1 antagonists as the active ingredient
WO2000071508A2 (fr) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. Inhibiteurs du facteur xa
JP2003500382A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子の阻害剤
KR20020022716A (ko) * 1999-06-24 2002-03-27 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 마크로파지 스캐빈저 수용체 길항제
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6360221B1 (en) * 1999-09-21 2002-03-19 Neostar, Inc. Method and apparatus for the production, delivery, and receipt of enhanced e-mail
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
FR2800074B1 (fr) 1999-10-22 2001-12-21 Aventis Pharma Sa Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant
WO2001035951A2 (fr) 1999-11-18 2001-05-25 Centaur Pharmaceuticals, Inc. Agent therapeutique a base d'arylnitrone et procedes de traitement des affections intestinales inflammatoires
DE10027151A1 (de) 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
EP1339668A2 (fr) 2000-11-28 2003-09-03 Guilford Pharmaceuticals Inc. Composes de liaison de cyclophiline carbocyclique bisubstituee et leur utilisation
US6498184B2 (en) 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
AU2002223958A1 (en) 2000-12-20 2002-07-01 Warner-Lambert Company Llc Non-halogenated phenoxy and/or benzyloxy phenols and antimicrobial compositions containing them
EP1369129A4 (fr) 2001-03-14 2005-08-03 Ono Pharmaceutical Co Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif

Also Published As

Publication number Publication date
HUP0304043A3 (en) 2005-05-30
AU2002338494B2 (en) 2007-05-10
CR7099A (es) 2004-02-20
US20030187033A1 (en) 2003-10-02
HK1064663A1 (en) 2005-02-04
DE10121003A1 (de) 2002-12-19
NZ529129A (en) 2005-11-25
IL158504A (en) 2010-11-30
ZA200306991B (en) 2004-08-31
CN100522937C (zh) 2009-08-05
MXPA03008419A (es) 2004-01-29
ECSP034780A (es) 2003-12-01
EE200300529A (et) 2004-02-16
NO328872B1 (no) 2010-06-07
SK13262003A3 (sk) 2004-03-02
JP2004527557A (ja) 2004-09-09
JP4231295B2 (ja) 2009-02-25
NO20034751L (no) 2003-11-13
EP1385820A1 (fr) 2004-02-04
EP1385820B1 (fr) 2011-10-12
PE20021088A1 (es) 2003-01-20
HRP20030871A2 (en) 2004-04-30
US7332608B2 (en) 2008-02-19
CA2445341A1 (fr) 2002-11-07
KR100865250B1 (ko) 2008-10-27
BR0209185A (pt) 2004-08-03
RU2283833C2 (ru) 2006-09-20
EE05267B1 (et) 2010-02-15
RS82003A (en) 2007-02-05
KR20040015198A (ko) 2004-02-18
OA12598A (fr) 2006-06-08
ATE528288T1 (de) 2011-10-15
NO20034751D0 (no) 2003-10-23
IL158504A0 (en) 2004-05-12
UA76986C2 (en) 2006-10-16
TNSN03084A1 (en) 2005-12-23
RU2003134544A (ru) 2005-03-27
US20070117807A1 (en) 2007-05-24
US7235690B2 (en) 2007-06-26
CN1522244A (zh) 2004-08-18
BG108215A (bg) 2004-09-30
HUP0304043A2 (hu) 2004-04-28
WO2002088073A1 (fr) 2002-11-07
TWI259833B (en) 2006-08-11
MY143521A (en) 2011-05-31
PL363433A1 (en) 2004-11-15
CA2445341C (fr) 2011-07-12
AR033623A1 (es) 2003-12-26
CZ20032921A3 (cs) 2004-01-14

Similar Documents

Publication Publication Date Title
MA27002A1 (fr) Amides d'acide anthranilique, procede pour les preparer, leur utilisation comme antiarythmiques et preparations pharmaceutiques les contenant
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TWI256950B (en) Indanyl-substituted benzenecarboxamides, processes for their preparation, their use as a medicament and pharmaceutical formulations containing them
MXPA03010875A (es) AMIDAS DE ACIDOS ANTRANILICOS CON CADENA LATERAL DE HETEROARILSULFONILO, PROCEDIMIENTO PARA SU PREPARACIoN SU EMPLEO COMO MEDICAMENTO O AGENTE DE DIAGNOSTICO ASI COMO PREPARADOS FARMACeUTICOS QUE LAS CONTIENEN.
KR940014337A (ko) 에이즈의 치료에 유용한 에이치아이브이(hiv) 프로테아제 억제제
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
MA31894B1 (fr) Composes organiques
DE69616749D1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
BR0215777A (pt) Composto, método para preparar o mesmo, composição farmacêutica para prevenir e tratar cardioisquemia, cerebroisquemia, oclusão arterial cerebral e para melhorar microcirculação do cérebro, e uso do composto
EA200200390A1 (ru) Новые оксабиспидиновые соединения, полезные при лечении сердечных аритмий
FR2856294B1 (fr) Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite
RU94046070A (ru) Применение /(4-(1,4,5,6-тетрагидро-4-метил-6-оксо-3-пиридазинил)фенил)гидразоно/ пропандинитрила для лечения или профилактики ишемии миокарда, способ лечения ишемии миокарда
TNSN03140A1 (fr) Derives d'acides sulfoniques nouveaux.
NL300198I1 (nl) Toepassing van 2-(2-nitro-4-trifluormethylbenzoyl)cyclohexaandion-1,3 voor het behandelen van tyrosinemie, alsmede farmaceutische preparaten.
DE69308514D1 (de) HIV-Protease Inhibitoren, verwendbar für die Behandlung von Aids
BRPI0110184B8 (pt) derivado de piridina-1-óxido, e processo para a sua transformação em compostos farmaceuticamente eficazes
TNSN90021A1 (fr) Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales
MA26725A1 (fr) Derives de resorcinol, compositions pharmaceutiques les contenant et procede pour leur preparation
KR940014336A (ko) 에이즈의 치료에 유용한 에이치아이브이(hiv) 프로테아제 억제제
MA56607A1 (fr) Méthodes de traitement de troubles dépressifs
ATE295367T1 (de) Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält
HRP20050815A2 (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound